Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Seattle startup Adaptive Biotechnologies that makes tools for cancer diagnosis and prognosis is seeking $20 million, according to a regulatory filing. The company has already raised $5 million. A filing from 2012 shows that Adaptive was seeking more than $5 million and ended up raising $2.65 million. Founded in 2009, Adaptive focuses on profiling the immune system. Its flagship product is the immunoSEQ, which the company describes as a "suite of next generation immune sequencing assays that allow researchers to view and analyze the T and B cells of the adaptive immune system with unprecedented depth and specificity."
Help employers find you! Check out all the jobs and post your resume.
Seattle startup Adaptive Biotechnologies that makes tools for cancer diagnosis and prognosis is seeking $20 million, according to a regulatory filing. The company has already raised $5 million. A filing from 2012 shows that Adaptive was seeking more than $5 million and ended up raising $2.65 million. Founded in 2009, Adaptive focuses on profiling the immune system. Its flagship product is the immunoSEQ, which the company describes as a "suite of next generation immune sequencing assays that allow researchers to view and analyze the T and B cells of the adaptive immune system with unprecedented depth and specificity."
Help employers find you! Check out all the jobs and post your resume.
